Jed Latkin, CEO, COO & CFO at NAVIDEA BIOPHARMACEUTICALS, INC. (NAVB), bought 2,500 shares at $1.45 ($4K) on 2019-05-16, disclosed to the SEC on 2019-05-17.
Open-market purchase of $4k NAVB by CEO, COO & CFO. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $1.45 | 1,500 | $2K | 59.8% |
| 2 | $1.46 | 1,000 | $1K | 40.2% |
| Total | $1.45 avg | 2,500 | $4K | 100% |
| Filing → |
| NAVB | BUY | 2019-05-15 | $10K | — | Filing → |
| NAVB | BUY | 2017-05-31 | $3K | — | Filing → |
| NAVB | BUY | 2017-05-23 | $11K | — | Filing → |